CN104011203A - 视网膜变性疾病的治疗方法 - Google Patents

视网膜变性疾病的治疗方法 Download PDF

Info

Publication number
CN104011203A
CN104011203A CN201280049453.2A CN201280049453A CN104011203A CN 104011203 A CN104011203 A CN 104011203A CN 201280049453 A CN201280049453 A CN 201280049453A CN 104011203 A CN104011203 A CN 104011203A
Authority
CN
China
Prior art keywords
cells
retinal
wnt
cell
signaling pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049453.2A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽亚·皮娅·卡斯马
丹妮拉·桑格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104011203A publication Critical patent/CN104011203A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280049453.2A 2011-08-05 2012-08-06 视网膜变性疾病的治疗方法 Pending CN104011203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11176713.3 2011-08-05
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (1)

Publication Number Publication Date
CN104011203A true CN104011203A (zh) 2014-08-27

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049453.2A Pending CN104011203A (zh) 2011-08-05 2012-08-06 视网膜变性疾病的治疗方法

Country Status (15)

Country Link
US (1) US20140199277A1 (enExample)
EP (2) EP2554662A1 (enExample)
JP (1) JP2014527407A (enExample)
KR (1) KR20140068936A (enExample)
CN (1) CN104011203A (enExample)
AR (1) AR087471A1 (enExample)
AU (1) AU2012293681A1 (enExample)
BR (1) BR112014002718A8 (enExample)
CA (1) CA2844106A1 (enExample)
CO (1) CO7081142A2 (enExample)
IL (1) IL230830A0 (enExample)
MX (1) MX2014001475A (enExample)
RU (1) RU2014108478A (enExample)
SG (1) SG2014008080A (enExample)
WO (1) WO2013020945A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603167A (zh) * 2015-09-15 2018-09-28 思特科技公司 使用其中引入nanog的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN109414416A (zh) * 2016-07-07 2019-03-01 国民大学校产学协力团 倍半萜衍生物的新用途
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889441A (zh) 2011-09-29 2014-06-25 伊丽莎白女王在都柏林附近神圣不可分割的三一学院教务长、研究员、学者及董事会其他成员 用于治疗退行性视网膜病况的组合物和方法
US11724005B2 (en) 2014-01-17 2023-08-15 Sumitomo Chemical Company, Limited Method for manufacturing ciliary margin stem cells
SG10201902285SA (en) * 2014-09-16 2019-04-29 Genzyme Corp Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7100019B2 (ja) * 2016-08-19 2022-07-12 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
BR112019022447A2 (pt) 2017-04-27 2020-06-09 Bober Miroslaw sistema e método para análise de imagem funduscópica automatizada
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド Ｎ－置換インドール誘導体
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
US20210139844A1 (en) * 2017-06-15 2021-05-13 University Of North Texas Health Science Center Reprogramming fibroblasts to retinal cells
EP3668487A4 (en) * 2017-08-20 2020-08-26 The Regents of the University of California MODULATION OF WNT5A TO TREAT GLAUCOMA
WO2019195717A1 (en) * 2018-04-06 2019-10-10 Icahn School Of Medicine At Mount Sinai Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
WO2020190848A1 (en) * 2019-03-15 2020-09-24 The Schepens Eye Research Institute, Inc. Isolation, enrichment and expansion of cone progenitor cells and uses thereof
US20230034053A1 (en) * 2019-09-25 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CN1816281A (zh) * 2003-05-02 2006-08-09 斯克里普斯研究学院 造血干细胞及其治疗新生血管性眼疾的方法
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2010029288A2 (en) * 2008-09-11 2010-03-18 Axordia Limited Growth factor
CN101835891A (zh) * 2007-06-15 2010-09-15 加内特生物治疗学股份有限公司 运用体外培养增殖的自我更新型集落形成细胞治疗疾病和功能紊乱症
WO2011043591A2 (en) * 2009-10-06 2011-04-14 Snu R&Db Foundation Method for differentiation into retinal cells from stem cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
PT1237880E (pt) 1999-12-17 2008-03-05 Novartis Vaccines & Diagnostic Inibidores baseados em pirazina da cinase 3 da glicogénio sintase
WO2001044246A1 (en) 1999-12-17 2001-06-21 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
DE60214703T2 (de) 2001-06-01 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
RU2004126671A (ru) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
EP1490093A4 (en) 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic METHOD AND COMPOSITIONS FOR TREATING ISCHEMIA
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
CA2502819A1 (en) 2002-10-21 2004-05-06 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20050054663A1 (en) 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
EP1802199A4 (en) * 2004-09-03 2008-08-27 Scripps Research Inst HEMATOPOIETIC STEM CELLS OF ISOLATED NEGATIVE LINES AND METHODS OF TREATMENT THEREOF
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
ES2382357T3 (es) 2005-02-24 2012-06-07 The Scripps Research Institute Células de tipo mieloide transfectadas para el tratamiento de retinopatía de la prematuridad y enfermedades relacionadas
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
ES2400916T3 (es) * 2005-06-08 2013-04-15 Janssen Biotech, Inc. Una terapia celular para degeneración ocular

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CN1816281A (zh) * 2003-05-02 2006-08-09 斯克里普斯研究学院 造血干细胞及其治疗新生血管性眼疾的方法
CN101835891A (zh) * 2007-06-15 2010-09-15 加内特生物治疗学股份有限公司 运用体外培养增殖的自我更新型集落形成细胞治疗疾病和功能紊乱症
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2010029288A2 (en) * 2008-09-11 2010-03-18 Axordia Limited Growth factor
WO2011043591A2 (en) * 2009-10-06 2011-04-14 Snu R&Db Foundation Method for differentiation into retinal cells from stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HITOMI AOKI ET AL.: "Embryonic stem cells that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo", 《EXPERIMENTAL EYE RESEARCH》 *
JIN-A KIM ET AL.: "Identification of a Stroma-Mediated Wnt/b-Catenin Signal Promoting Self-Renewal of Hematopoietic Stem Cells in the Stem Cell Niche", 《STEM CELLS》 *
TOSHIHIRO INOUE ET AL.: "Activation of Canonical Wnt Pathway Promotes Proliferation of Retinal Stem Cells Derived from Adult Mouse Ciliary Margin", 《STEM CELLS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603167A (zh) * 2015-09-15 2018-09-28 思特科技公司 使用其中引入nanog的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN108603167B (zh) * 2015-09-15 2022-01-21 思特科技公司 使用nanog引入的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN109414416A (zh) * 2016-07-07 2019-03-01 国民大学校产学协力团 倍半萜衍生物的新用途
CN109414416B (zh) * 2016-07-07 2021-03-26 国民大学校产学协力团 倍半萜衍生物的新用途
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜

Also Published As

Publication number Publication date
RU2014108478A (ru) 2015-09-10
BR112014002718A2 (pt) 2017-06-13
BR112014002718A8 (pt) 2017-06-20
AR087471A1 (es) 2014-03-26
WO2013020945A1 (en) 2013-02-14
IL230830A0 (en) 2014-03-31
EP2554662A1 (en) 2013-02-06
CA2844106A1 (en) 2013-02-14
CO7081142A2 (es) 2014-10-10
SG2014008080A (en) 2014-03-28
KR20140068936A (ko) 2014-06-09
MX2014001475A (es) 2014-07-22
JP2014527407A (ja) 2014-10-16
NZ621345A (en) 2015-09-25
AU2012293681A1 (en) 2014-03-06
WO2013020945A9 (en) 2013-04-04
EP2739723A1 (en) 2014-06-11
US20140199277A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
CN104011203A (zh) 视网膜变性疾病的治疗方法
Sanges et al. Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors
US10787641B2 (en) Therapeutic use of CD31 expressing cells
Huang et al. Stem cell-based therapeutic applications in retinal degenerative diseases
TWI698242B (zh) 利用血管母細胞產生間葉基質細胞之方法
CN101484575B (zh) 用于眼变性的细胞疗法
Kemp et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells
Huang et al. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart
JP2025028314A (ja) 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
Mussar et al. Macrophage/epithelium cross-talk regulates cell cycle progression and migration in pancreatic progenitors
KR20120060201A (ko) 기능적으로 분화된 체세포의 연장된 자기재생을 유도하는 방법
KR20170093178A (ko) 전구 세포를 사용한 안구 질환의 치료
CA2628530C (en) Novel stem cells, nucleotide sequences and proteins therefrom
JPWO2015125941A1 (ja) 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法
CN120112629A (zh) T细胞产生方法
KR20180088713A (ko) 전구 세포를 사용한 망막 변성의 치료
JP2023513632A (ja) 血小板由来ミトコンドリア治療及び多能性細胞の生成方法
NZ621345B2 (en) Methods of treatment of retinal degeneration diseases
ALSHARIF Thymic recovery following chemotherapy damage–the impact of sex hormones and ageing
WO2022009969A1 (ja) 網膜色素上皮細胞の移植用生着促進剤
Erika The immunomodulatory and pro-regenerative capacity of mesenchymal stromal cells and their therapeutic use for kidney disease
Tysoe The Immunogenicity of Cholangiocyte Cellular Therapies
Morad Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis
Mathews Ex vivo expansion and induced transdifferentiation of rabbit bone marrow messenchymal stem cells to corneal lineage by simulating corneal stem cell niche
Tan et al. Hematopoietic stem cells and somatic stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140827

WD01 Invention patent application deemed withdrawn after publication